Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non–small-cell Lung Cancer Developing After Surgery-Reference-Cited by-同舟云学术

Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non–small-cell Lung Cancer Developing After Surgery

Published:2017-11 Issue:6 Volume:18 Page:e441-e448
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Nakamichi Shinji,Horinouchi Hidehito^ORCID,Asao Tetsuhiko,Goto Yasushi,Kanda Shintaro,Fujiwara Yutaka,Nokihara Hiroshi,Yamamoto Noboru,Ito Yoshinori,Watanabe Shun-ichi,Ohe Yuichiro

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Local and systemic recurrence is the Achilles Heel of cancer surgery;Aliperti;Ann Surg Oncol,2011

2. Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade;Sawabata;J Thorac Oncol,2011

3. Local recurrence after complete resection for non-small-cell carcinoma of the lung. Significance of local control by radiation treatment;Yano;J Thorac Cardiovasc Surg,1994

4. Local recurrence following lung cancer surgery: incidence, risk factors, and outcomes;Fedor;Surg Oncol,2013

5. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer;Yano;World J Clin Oncol,2014

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy;Molecular Cancer Therapeutics;2024-04-26

2. Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling study;Lung Cancer;2023-10

3. Cost–effectiveness of adjuvant atezolizumab for patients with stage II–IIIA PD-L1+ non-small-cell lung cancer;Immunotherapy;2023-06

4. Adjuvant chemotherapy, not radiotherapy, prolongs survival for node-negative non–small cell lung cancer with positive surgical margins;JTCVS Open;2023-06

5. Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective;Lung Cancer;2023-05